Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research

Toni K. Choueiri, Michael B. Atkins, Ziad Bakouny, Maria I. Carlo, Charles G. Drake, Eric Jonasch, Payal Kapur, Bryan Lewis, W. Marston Linehan, Michael J. Mitchell, Sumanta K. Pal, Kevin Pels, Susan Poteat, W. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar Tannir, Robert Uzzo, Christopher G. Wood, Hans J. Hammers

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Kidney cancer is one of the 10 most common cancers both in the United States and worldwide. Until this year, there had not previously been a conference focused on translational studies in the broad and heterogeneous group of kidney cancers. Therefore, a group of researchers, clinicians, and patient advocates dedicated to renal cell carcinoma launched the Kidney Cancer Research Summit (KCRS) to spur collaboration and further therapeutic advances in these tumors. This commentary aims to summarize the oral presentations and serve as a record for future iterations of this meeting. The KCRS sessions addressed the tumor microenvironment, novel methods of drug delivery, single cell sequencing strategies, novel immune checkpoint blockade and cellular therapies, predictive biomarkers, and rare variants of kidney cancers. In addition, the meeting included 2 sessions to promote scientific mentoring and kidney cancer research collaborations. A subsequent KCRS will be planned for the fall of 2020.

Original languageEnglish (US)
Pages (from-to)234-243
Number of pages10
JournalJournal of the National Cancer Institute
Issue number3
StatePublished - Mar 1 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research'. Together they form a unique fingerprint.

Cite this